In fairness, the quarterly did mention DEP Gemcitabine as (still) at the pre-clinical stage. I wonder if they are trying to find someone else to pay for the trial? Regardless of how long it takes.
Business development activities for DEP® cabazitaxel, DEP® irinotecan, and DEP® docetaxel are ongoing. Other internal preclinical DEP® programs including DEP® radiotheranostics, DEP® ADCs, and DEP® gemcitabine continue to progress, with ongoing commercial discussions in parallel.
Status quo to win out?, page-5
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |